ctDNA定量改善高级别骨肉瘤患者结局评估:来自OS2006试验的转化研究
该转化研究基于前瞻性OS2006方案中183例高级别骨肉瘤患者,采用低深度全基因组测序检测诊断时、手术前及治疗结束时的循环肿瘤DNA(ctDNA)。诊断时ctDNA定量是独立于转移状态的主要预后因素,加入转移状态或组织学反应可改善预后分层,并开发了PRONOS预测工具。手术时及治疗结束时的ctDNA定量仍需改进,外部验证正在Sar coma 13试验中进行。
要点
- 诊断时ctDNA定量是独立于转移状态的主要预后因素(PFS HR=3.5,P=0.002;OS HR=3.51,P=0.012)。
- 手术时及治疗结束时ctDNA定量独立于组织学反应预测预后(PFS HR=9.2,P<0.001;OS HR=11.6,P<0.001)。
- 将诊断时ctDNA定量加入转移状态或术后组织学反应可改善预后分层,并开发了PRONOS预测工具。
核心结论
- 将ctDNA定量加入已知风险因素可改善PRONOS预测工具计算的预后估计。
- 为确认其价值,正在Sar coma 13试验中进行外部验证。
研究设计与样本
- 前瞻性OS2006方案中均一治疗的183例高级别骨肉瘤患者,采集诊断时、手术前及治疗结束时的血浆。
- 采用低深度全基因组测序(lpWGS)检测拷贝数变异。
- 开发包含ctDNA定量和已知临床参数的预测工具以估计个体事件风险。
主要发现
- 诊断时ctDNA定量(diagCPA)作为连续变量是独立于其他临床参数(包括转移状态)的主要预后因素:PFS HR=3.5,P=0.002;OS HR=3.51,P=0.012。
- 手术时及治疗结束时,diagCPA独立于组织学反应预测预后:PFS HR=9.2,P<0.001;OS HR=11.6,P<0.001。
- 将diagCPA加入诊断时转移状态或术后不良组织学反应可改善骨肉瘤患者的预后分层。
- 手术时及治疗结束时的ctDNA定量仍需改进,以克服lpWGS的低灵敏度并实现疾病进展随访。
临床怎么用
- 原文未据此给出推荐。
局限性
- 手术时及治疗结束时的ctDNA定量仍需改进,以克服lpWGS的低灵敏度并实现疾病进展随访。
- 需在Sar coma 13试验中进行外部验证以确认PRONOS预测工具的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteosarcoma stratification relies on clinical parameters and histological response. We developed a new personalized stratification using less invasive circulating tumor DNA (ctDNA) quantification. PATIENTS AND METHODS: Plasma from patients homogeneously treated in the prospective protocol OS2006, at diagnosis, before surgery and end of treatment, were sequenced using low-passage whole-genome sequencing (lpWGS) for copy number alteration detection. We developed a prediction tool including ctDNA quantification and known clinical parameters to estimate patients' individual risk of event. RESULTS: ctDNA quantification at diagnosis (diagCPA) was evaluated for 183 patients of the protocol OS2006. diagCPA as a continuous variable was a major prognostic factor, independent of other clinical parameters, including metastatic status [diagCPA hazard ratio (HR) = 3.5, P = 0.002 and 3.51, P = 0.012, for progression-free survival (PFS) and overall survival (OS)]. At the time of surgery and until the end of treatment, diagCPA was also a major prognostic factor independent of histological response (diagCPA HR = 9.2, P < 0.001 and 11.6, P < 0.001, for PFS and OS). Therefore, the addition of diagCPA to metastatic status at diagnosis or poor histological response after surgery improved the prognostic stratification of patients with osteosarcoma. We developed the prediction tool PRONOS to generate individual risk estimations, showing great performance ctDNA quantification at the time of surgery and the end of treatment still required improvement to overcome the low sensitivity of lpWGS and to enable the follow-up of disease progression. CONCLUSIONS: The addition of ctDNA quantification to known risk factors improves the estimation of prognosis calculated by our prediction tool PRONOS. To confirm its value, an external validation in the Sarcoma 13 trial is underway.
引用
- Audinot B, Drubay D, Gaspar N, et al. ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial. Ann Oncol. 2023. PMID: 38142939. doi:10.1016/j.annonc.2023.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。